伊戈爾(002922.SZ)擬註銷德國子公司
格隆匯 11 月 9日丨伊戈爾(002922.SZ)公佈,公司於2020年11月06日召開第五屆董事會第八次會議,會議審議通過了《關於註銷德國子公司的議案》。根據公司戰略及業務發展需要,公司擬註銷全資子公司Sunrise Power Transformers GmbH(“德國伊戈爾”),以優化資產結構、提高公司整體經營效率。根據《公司章程》的規定,此次註銷事項無需提交股東大會審議批准。
此次註銷德國伊戈爾有利於公司降低經營管理成本、提高管理效率,不會對公司的整體業務發展及盈利水平產生重大影響,不會對公司合併報表產生實質性的影響,不存在損害公司及中小股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.